LK-1

N/A

Report date: 2025/06/11 10:19:24

Base Information

Drug NameLK-1

Drug Alias Nameangiogensis inhibitor (Lykera Biomed SA)anticancer monoclonal antibody (Lykera)S100 calcium binding protein A4 inhibitor (Lykera Biomed SA)metastasis inhibitor (Lykera Biomed SA)5C3 +[6]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionImmunomodulatorsAngiogenesis inhibitorsMetastasis inhibitors +[4]

TargetsProtein S100-A4

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLykera Biomed Sa

China Registration ClassN/A

Develop Information

Active CompaniesLykera Biomed Sa

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A